Top Page
OncoSil Medical Ltd
(Sydney:OSL)
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
OncoSil Medical Ltd Business Overview & Revenue Model
OncoSil Medical Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01M | 1.17M | 516.63K | 367.68K | 231.79K | 213.07K |
| Gross Profit | -4.06M | -1.08M | -993.00K | -1.22M | -6.73M | -748.00K |
| EBITDA | -15.08M | -15.06M | -12.91M | -11.17M | -11.41M | -11.31M |
| Net Income | -15.10M | -15.10M | -11.91M | -11.34M | -10.73M | -10.43M |
Balance Sheet | ||||||
| Total Assets | 7.15M | 7.15M | 6.72M | 11.47M | 13.07M | 14.15M |
| Cash, Cash Equivalents and Short-Term Investments | 5.11M | 5.11M | 4.50M | 9.39M | 11.28M | 12.24M |
| Total Debt | 69.92K | 69.92K | 70.67K | 170.81K | 304.21K | 484.37K |
| Total Liabilities | 4.04M | 4.04M | 1.98M | 1.59M | 1.91M | 2.45M |
| Stockholders Equity | 3.10M | 3.10M | 4.74M | 9.88M | 11.16M | 11.70M |
Cash Flow | ||||||
| Free Cash Flow | -12.08M | -12.08M | -11.02M | -11.37M | -10.12M | -8.87M |
| Operating Cash Flow | -12.06M | -12.06M | -10.82M | -11.32M | -10.11M | -8.82M |
| Investing Cash Flow | -14.96K | -14.96K | -197.06K | -57.82K | -5.83K | -54.00K |
| Financing Cash Flow | 12.73M | 12.73M | 6.13M | 9.49M | 9.16M | 111.25K |
OncoSil Medical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$13.43M | -1.63 | -103.74% | ― | 14.84% | 39.64% | |
50 Neutral | AU$70.02M | -5.38 | -31.98% | ― | 34.20% | -23.90% | |
47 Neutral | AU$830.45M | -22.71 | -44.49% | ― | 55.91% | 22.60% | |
44 Neutral | AU$171.94M | -16.13 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$58.10M | ― | -128.19% | ― | -14.25% | -22.83% | |
39 Underperform | AU$24.85M | -0.95 | -385.20% | ― | 126.62% | 33.53% |
OncoSil Medical Ltd Corporate Events
OncoSil Medical Limited announced promising interim results from the OSPREY registry, showing improved survival rates for LAPC patients treated with the OncoSil™ device and chemotherapy. The findings indicate a significant survival advantage compared to standard chemotherapy alone, with a favorable safety profile, potentially impacting the company’s market position and offering hope for improved patient outcomes.
OncoSil Medical Limited announced a change in the director’s interest, with Lelde Smits acquiring 41,067 shares in lieu of cash director fees for the period from October 2025 to September 2026. This move, approved by shareholders at the 2025 Annual General Meeting, reflects the company’s strategic approach to align director incentives with company performance, potentially impacting stakeholder confidence and the company’s market positioning.
OncoSil Medical Ltd has announced the issuance of new unquoted equity securities, specifically options set to expire in 2028 and 2030, with an exercise price of $1.80. This move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing capital resources, thereby supporting its ongoing operations and strategic initiatives.
OncoSil Medical Ltd has announced the application for quotation of 82,134 ordinary fully paid securities on the Australian Securities Exchange (ASX), following shareholder approval at the 2025 AGM. This move is part of the company’s strategic efforts to enhance its financial standing and operational capabilities, potentially impacting its market position and offering new opportunities for stakeholders.
OncoSil Medical Ltd announced the cessation of Douglas Cubbin as a director of the company as of November 19, 2025. This change in the board may impact the company’s strategic direction and governance. The announcement also detailed Cubbin’s interests in the company’s securities, including the lapse of 12,500 unlisted options upon his departure. The update is significant for stakeholders as it reflects changes in leadership and potential shifts in company policy or focus.
OncoSil Medical Ltd announced the cessation of 12,500 securities due to the lapse of conditional rights, as the conditions for these securities were not met. This development may impact the company’s financial structure and could influence investor perceptions, although the broader implications for stakeholders remain to be seen.
OncoSil Medical Limited announced that its CEO, Nigel Lange, will present at the 2025 Bell Potter Healthcare Conference in Sydney, Australia. This presentation underscores OncoSil’s commitment to advancing its position in the medical device sector, particularly in the treatment of pancreatic cancer, and highlights the company’s ongoing efforts to expand its market presence and stakeholder engagement.
OncoSil Medical Limited announced that all resolutions at its Annual General Meeting were approved by poll. This outcome reflects strong shareholder support for the company’s strategic direction and operational decisions, potentially reinforcing its position in the medical device industry focused on cancer treatment.
OncoSil Medical Limited announced significant achievements in FY25, including regulatory progress and commercial expansion. The approval from Germany’s G-BA for a fully funded clinical trial is expected to enhance access to the OncoSil™ device in the German public hospital system, potentially influencing reimbursement negotiations across Europe. Additionally, the company achieved MDR certification, streamlining treatment initiation in the EU and UK, and recorded its first commercial sale in Germany. Clinical trials like PANCOSIL and TRIPP-FFX are nearing completion, with promising results supporting the efficacy of the OncoSil™ device.
OncoSil Medical Limited announced the retirement of Independent Non-Executive Director Doug Cubbin, who will not stand for re-election at the upcoming AGM. During his tenure, Cubbin played a crucial role in advancing the development and commercialization strategies for the OncoSil™ device, which has now entered key markets including the US, EU, and Middle East. His leadership contributed to the company’s growth and the successful market entry of their innovative cancer treatment technology.
OncoSil Medical Ltd reported record cash receipts for Q1 FY26, marking a 917% increase from the previous year, driven by increased sales and growing adoption of its OncoSil™ device. The company announced positive preliminary results from the PANCOSIL Phase 1-2 Study, indicating the safety and feasibility of their CT-guided percutaneous administration approach, which could lead to expanded treatment options for pancreatic cancer patients. Additionally, Dr. Thomas Duthy was appointed as Non-Executive Chairman, reinforcing the company’s strategic focus on advancing its position in the oncology device sector.
OncoSil Medical Ltd addressed compliance queries from the ASX regarding its involvement in the PANCOSIL study conducted by Amsterdam University Medical Centre. The study focused on the feasibility of using OncoSil™ for treating non-progressive locally advanced pancreatic cancer. OncoSil provided doses and funding for the study, but the data was owned by Amsterdam UMC. The company faced challenges in meeting disclosure obligations due to a lack of prior access to the study data, leading to a trading halt to analyze the results. OncoSil has since implemented additional training for its executive team to prevent future oversights.
OncoSil Medical Ltd announced the cessation of 18,942 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders, as it reflects on the company’s operational challenges in meeting set conditions for securities.
OncoSil Medical Ltd has announced its Annual General Meeting (AGM) scheduled for November 19, 2025, at K&L Gates in Melbourne. Shareholders are invited to participate in the meeting, with options to vote online or by proxy if unable to attend. This meeting is a significant event for stakeholders, providing an opportunity to discuss the company’s progress and future strategies.
OncoSil Medical Ltd recently addressed a query from the ASX regarding the disclosure of results from the PANCOSIL trial, a Phase 1-2 feasibility study conducted by Amsterdam University Medical Centre. The trial, which investigates the safety and feasibility of CT-guided percutaneous placement of the OncoSil™ device, showed promising preliminary results, including a 90% feasibility rate for tumor ablation. The company promptly implemented a trading halt to analyze the results and released an announcement to the ASX, highlighting the potential impact of these findings on their operations and market positioning.
OncoSil Medical Ltd has released a presentation to provide an overview of its operations and future prospects. The company is focused on the development of medical devices for cancer treatment, specifically targeting pancreatic cancer. The presentation includes forward-looking statements about potential regulatory approvals and commercial success, although it cautions that actual results may differ due to various risks and uncertainties. Stakeholders are advised to consider these factors and seek independent advice when evaluating the company’s future performance.
OncoSil Medical Ltd has announced positive preliminary results from its PANCOSIL Phase 1-2 study, which demonstrates the safety and feasibility of delivering the OncoSil™ device via CT-guided percutaneous administration for treating locally advanced pancreatic cancer. The study showed a 90% technical success rate and a median overall survival of 20.6 months, surpassing the typical 13 months for LAPC. These findings could lead to further regulatory approvals and expand the use of OncoSil™ therapy, potentially transforming treatment delivery and increasing adoption in clinical practice.
OncoSil Medical Limited has announced an investor webinar scheduled for 18 September 2025, where CEO Nigel Lange will discuss preliminary results from the PANCOSIL Investigator Initiated Study. This event highlights OncoSil’s ongoing efforts to engage with stakeholders and provide updates on their innovative cancer treatment solutions, potentially impacting their market positioning and stakeholder relations.
OncoSil Medical Limited has announced that its Annual General Meeting will be held on November 19, 2025, in Melbourne, with the deadline for director nominations set for October 1, 2025. This announcement is significant for stakeholders as it outlines the company’s governance timeline and provides an opportunity for shareholder engagement. Further details about the AGM will be shared in the Notice of Meeting, highlighting the company’s commitment to transparency and shareholder communication.
OncoSil Medical Ltd announced the issuance of 2,322 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, confirming compliance with relevant legal provisions and the absence of excluded information. This move reflects the company’s ongoing efforts to strengthen its financial position and support its strategic initiatives in the medical device sector, particularly in expanding the reach and application of its OncoSil™ device for pancreatic cancer treatment.
OncoSil Medical Ltd has announced the quotation of 2,322 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 10, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing operations, potentially impacting its market position and offering new opportunities for stakeholders.
OncoSil Medical Limited has announced the appointment of Dr. Thomas Duthy as the new Non-Executive Chairman, effective 1 October 2025. Dr. Duthy, who brings over 20 years of experience in healthcare and technology, replaces Mr. Doug Cubbin, who will transition to a Non-Executive Director role. This strategic change is expected to support OncoSil’s growth in existing and new markets, as well as enhance clinical data generation to boost clinician adoption and market access. The announcement reflects OncoSil’s ongoing commitment to advancing its OncoSil™ device and achieving key milestones for its availability in targeted regions.